Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-06-25 02:01 UTC

BIOMED PULSE

June 25, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 896 confirmed cases and 232 deaths as of June 17, remaining a full WHO Public Health Emergency of International Concern - the defining crisis of this moment. [1]

The mood is urgent but engaged: a new WHO filovirus treatment guideline, an Africa CDC-WHO joint response plan seeking $518 million, and active airport screening signal a coordinated global mobilization. [2] [3]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS - DRC AND UGANDA (PHEIC)

  • As of June 17, 2026, 896 confirmed cases and 232 confirmed deaths have been reported from the Democratic Republic of the Congo, with cross-border transmission continuing into Uganda. [1]
  • WHO declared this Bundibugyo virus disease (BVD) outbreak a Public Health Emergency of International Concern on May 16-17, 2026; the IHR Emergency Committee confirmed it does not yet meet criteria for a pandemic emergency. [4] [5]
  • Africa CDC and WHO launched a joint continental preparedness and response plan on June 5, 2026, seeking to raise US$518 million to support African countries' response capacity. [3]
  • WHO released its first-ever comprehensive clinical management guidelines for filovirus diseases - covering all Ebola types and Marburg - on June 17, 2026, directly timed to support this outbreak response. [2]
  • CDC has mobilized an international Ebola response, expanded enhanced airport screening to Washington-Dulles International Airport and Atlanta Hartsfield-Jackson, and activated a World Cup 2026 public health presence. [6] [7] [8]
  • WHO experts convened in late May assessed candidate vaccines and therapeutics for Bundibugyo virus specifically, noting that no approved products currently exist for this Ebola subtype. [9]

HANTAVIRUS - M/V HONDIUS CRUISE SHIP (MULTI-COUNTRY)

  • The fourth WHO Disease Outbreak News report (May 28, 2026) confirmed the pathogen as Andes hantavirus; the outbreak was linked to the M/V Hondius cruise ship carrying passengers from 23 countries. [10]
  • CDC issued its most recent hantavirus response transcript on June 24, 2026, indicating monitoring and case-tracking is still active.
  • WHO Director-General issued a direct message of thanks to the people of Tenerife for their cooperation in safely disembarking and caring for over 120 passengers during the response operation.

YELLOW FEVER - GLOBAL

  • From January 1 to May 26, 2026, six countries reported a total of 79 human yellow fever infections; the WHO Disease Outbreak News (June 24, 2026) notes transmission activity carried over from elevated 2025 activity in the Americas.

MPOX - RECOMBINANT STRAIN

  • WHO reported in February 2026 two cases of a recombinant monkeypox virus strain combining genomic elements of clades Ib and IIb, flagging natural recombination as a surveillance concern when two strains co-infect one individual.

NIPAH VIRUS - INDIA AND BANGLADESH

  • India reported two confirmed Nipah virus infections in healthcare workers at a private hospital in Barasat, West Bengal (notified January 26, 2026); Bangladesh reported one confirmed case in Rajshahi Division with onset January 21, 2026.

MEASLES - BANGLADESH

  • Bangladesh reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts as of the WHO DON issued April 23, 2026, underscoring the global measles resurgence.

MERS-COV - GLOBAL

  • WHO's December 2025 global update recorded 19 MERS-CoV cases (including 4 deaths) since January 2025; 17 of those cases were in Saudi Arabia, with 2 in France, and no evidence of sustained human-to-human transmission.

LISTERIA - REQUESÓN/SOFT RICOTTA CHEESE

  • CDC warned on June 5, 2026 of a new Listeria monocytogenes outbreak linked to requesón/soft ricotta cheese; consumers are advised not to eat the implicated product.

SALMONELLA - MULTIPLE ACTIVE OUTBREAKS

  • An active Salmonella outbreak linked to eggs was posted by CDC on June 7, 2025, and a separate outbreak tied to pistachio cream (4 cases) was announced June 16, 2025.
  • An ongoing and growing CDC alert flagged a rising number of Salmonella illnesses linked to moringa leaf products across multiple outbreaks as of May 27, 2026.

LISTERIA - CHICKEN FETTUCCINE ALFREDO MEALS

  • CDC warned on June 19, 2025 of 17 illnesses from the same Listeria strain tied to recalled chicken fettuccine alfredo meals; consumers are urged to check for recalled products.

INFANT BOTULISM - POWDERED FORMULA

  • CDC issued an outbreak update on June 13, 2026 urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula linked to infant botulism cases.

NEW WORLD SCREWWORM

  • CDC activated its Emergency Operations Center on June 12, 2026 for a New World Screwworm response, a parasitic fly (Cochliomyia hominivorax) that can infest living tissue of humans and animals.

🧬 LONGEVITY & AGING

CELLULAR SENESCENCE AND KIDNEY REPAIR

  • A study published in Ren Fail (June 14, 2026) found that the enzyme AMD1, which governs polyamine metabolism, controls whether kidney tubular cells repair themselves or enter cellular senescence after injury - identifying a potential target to push damaged tissue toward regeneration rather than permanent aging.

DNA METHYLATION, TELOMERE LENGTH, AND BRAIN ANEURYSM RISK

  • A genetic study published in IBRO Neuroscience Reports (May 30, 2026) used Mendelian randomization to show that DNA methylation-estimated biological age and shorter telomere length are each independently associated with increased risk of intracranial aneurysms, linking epigenetic aging clocks to vascular disease.

HYPERTENSION AND FRAILTY IN OLDER ADULTS

  • A longitudinal cohort study using data from the Longitudinal Ageing Study in India (published Blood Press, June 21, 2026) found significant associations between hypertension and frailty among middle-aged and older Indian adults, adding to evidence that blood pressure control matters for preserving physical resilience with age.

HANDGRIP STRENGTH AND DIGESTIVE DISEASE IN OLDER ADULTS

  • A prospective parallel-analysis study across Chinese and European older adults (Glob Health Action, June 15, 2026) found that lower combined handgrip strength predicted higher incidence of multiple chronic digestive diseases, reinforcing grip strength as a practical, inexpensive marker of systemic aging.

CHONDROCYTE DEDIFFERENTIATION AND SENESCENCE

  • Researchers publishing in Regenerative Therapy (June 13, 2026) identified a conserved nine-gene decline module in long-term expanded auricular chondrocytes, showing that cartilage cell aging via dedifferentiation can occur independently of classical cellular senescence pathways - relevant for cartilage repair and tissue engineering in aging populations.

GUT-DERIVED UREMIC TOXINS AND CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME

  • A review in Gut Microbes (June 15, 2026) examined how gut microbiome-derived uremic toxins drive the cardiovascular-kidney-metabolic syndrome triad, proposing the gut-kidney-heart axis as a key target for interventions aimed at slowing multiorgan aging.

COLLAGEN OXIDATION AND TISSUE AGING

  • A review published in Redox Reports (June 11, 2026) detailed how both enzymatic and non-enzymatic oxidation of fibrillar collagen degrade its structural integrity with age, linking oxidative stress to the mechanical decline of connective tissues, skin, and bone.

MULTIPLE LONG-TERM CONDITIONS AND CHRONIC KIDNEY DISEASE OUTCOMES

  • The NURTuRE-CKD multicentre cohort study (Ann Med, June 23, 2026) found that the accumulation of multiple long-term conditions in people with chronic kidney disease significantly accelerates mortality, kidney failure progression, and worsens health-related quality of life - quantifying the compounding burden of multimorbidity in aging.

💊 NEW CURES & APPROVALS

RINVOQ LQ (UPADACITINIB) - ABBVIE

  • AbbVie received a supplemental approval (SUPPL AP) for Rinvoq LQ (upadacitinib), a JAK1-selective inhibitor, under NDA218347; upadacitinib is approved for multiple inflammatory indications including rheumatoid arthritis, atopic dermatitis, and ulcerative colitis.

NOTE ON FDA DRUG DATA

  • The remaining openFDA supplemental approvals in today's data batch cover generic opioid reformulations (oxycodone, hydrocodone, tapentadol, methadone, meperidine, codeine, butorphanol) by manufacturers including Hibrow Healthcare, Amneal Pharmaceuticals, SpecGx LLC, Epic Pharma, Hikma, and Rising; these are supply-chain label or formulation updates, not new therapeutic breakthroughs.

🧪 CLINICAL TRIALS

PEMBROLIZUMAB FOR NEUROLOGICAL LONG COVID (PD1-PASC I) - NCT07388550

  • A Phase I open-label safety trial registered June 24, 2026, is testing the checkpoint inhibitor pembrolizumab (anti-PD-1) in patients with neurological post-acute sequelae of SARS-CoV-2 (neuro-PASC), hypothesizing that persistent viral antigen-driven immune activation can be reset - a novel immunological rationale for treating long COVID brain fog, headache, and gait problems.

WALKASINS DEVICE FOR PERIPHERAL NEUROPATHY BALANCE - NCT06959277

  • A six-month clinical trial registered June 24, 2026, is testing whether the Walkasins wearable leg cuff, which provides vibrotactile sensory feedback, can improve balance awareness and reduce falls in older adults with peripheral neuropathy - a common aging complication.

FLEXOR HALLUCIS LONGUS TRAINING AND FALL PREVENTION IN GERIATRICS - NCT06887478

  • A trial registered June 24, 2026 is examining whether targeted strengthening of the flexor hallucis longus (big-toe flexor) muscle improves balance and gait parameters and reduces falls in geriatric patients, building on data showing toe flexor weakness is an independent fall predictor.

ISOMETRIC RESISTANCE EXERCISE ON ATHEROSCLEROSIS IN HYPERTENSION - NCT07665034

  • A trial registered June 24, 2026 is investigating whether isometric resistance exercise (such as wall squats) - which create sustained muscle tension without joint movement - can improve blood pressure control and slow accelerated atherosclerosis in hypertensive patients, relevant to cardiovascular aging.

HIV SKIN, MUSCLE, AND BONE AGING BIOMARKERS - NCT04067219

  • An ongoing study registered on ClinicalTrials.gov is comparing markers of skin, muscular, neurocognitive, and bone aging between HIV-infected adults and age-matched general population controls, aiming to quantify accelerated aging driven by HIV infection and antiretroviral therapy.

PEMBROLIZUMAB PLUS LENVATINIB IN CUTANEOUS ANGIOSARCOMA - NCT06673628

  • A trial registered June 24, 2026 is evaluating combined PD-1 blockade (pembrolizumab) and VEGFR inhibition (lenvatinib) in unresectable cutaneous angiosarcoma, a rare vascular cancer whose incidence rises with age and which is increasing as populations grow older.

(2R,6R)-HYDROXYNORKETAMINE (HNK) AS A NON-OPIOID ANALGESIC - NCT07504601

  • A Phase I trial registered June 24, 2026 is testing a single dose of (2R,6R)-HNK - a ketamine metabolite without addiction liability - for acute pain in healthy volunteers, addressing the urgent need for non-opioid pain drugs in the context of over 14,000 opioid overdose deaths annually.

📢 PUBLIC HEALTH

ACIP MEETING CONCLUDES JUNE 25-26, 2026

  • CDC's Advisory Committee on Immunization Practices held its scheduled meeting June 25-26, 2026, concluding with a joint statement; agenda items and results are being posted online.

CDC IMMUNIZATION SCHEDULE SHIFTS TO INDIVIDUAL-BASED COVID-19 DECISION-MAKING

  • Effective October 2025, CDC updated its adult and child immunization schedules to apply individual-based clinical decision-making for COVID-19 vaccination and to allow standalone varicella vaccination for toddlers, departing from prior universal-recommendation language.

WHO: UNSAFE FOOD KILLS 1.5 MILLION PEOPLE ANNUALLY

  • WHO released updated estimates on June 3-4, 2026 showing unsafe food causes 866 million illnesses and 1.5 million deaths per year globally; children under five face nearly three times the illness risk of older individuals.

CDC DRUG-RESISTANT BACTERIA REPORT

  • A CDC report released September 23, 2025 found a dramatic increase in dangerous drug-resistant bacteria in the United States, continuing the antimicrobial resistance trend flagged in prior years.

CONGENITAL SYPHILIS - 12TH CONSECUTIVE YEAR OF INCREASE

  • CDC data released September 24, 2025 showed U.S. newborn syphilis cases increased for the 12th straight year in 2024, reflecting ongoing gaps in prenatal STI screening and treatment.

CDC TRAVELER-BASED GENOMIC SURVEILLANCE SURPASSES 1 MILLION PARTICIPANTS

  • CDC's airport-based Traveler-Based Genomic Surveillance program crossed one million voluntary air travel participants as of January 30, 2026, a key tool for early detection of emerging pathogen variants.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — WHO Disease Outbreak News
  2. WHO issues comprehensive guidelines on filovirus disease, including Ebola and Marburg disease — WHO News
  3. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  4. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a pub — WHO News
  5. First meeting of the IHR Emergency Committee regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic — WHO News
  6. Enhanced Ebola Airport Screening Begins at Washington-Dulles International Airport — CDC Newsroom
  7. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  8. Transcript - Update on Ebola Outbreak in the Democratic Republic of the Congo and Uganda and CDC's World Cup 2026(TM) ac — CDC Newsroom
  9. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus — WHO News
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260625-02-v11 · 2026-06-25 02:01 UTC

Read next